本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2023 年 8 月 8 日 | 1、出席会议的股东和代理人人数 | 5 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 63,473,914 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 40.5606 | 注：截至本次股东大会股权登记日（2023 年 8 月 2 日），北京康辰药业股份 有限公司（以下简称"公司"）总股本 160,000,000 股，回购专用证券账户股份 数为 3,508,623 股，因公司所持有的本公司股份没有表决权，故此次股东大会有 表决权的股份总数为 156,491,377 股。 证券代码：603590 证券简称：康辰药业 公告编号：临 2023-050 北京康辰药业股份有限公司 2023 年第二次临时股东大会决议公告 | 股东类型 | | 同意 | | 反对 | | ...

北京国枫律师事务所 关于北京康辰药业股份有限公司 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出 席并见证贵公司 2023 年第二次临时股东大会（以下简称"本次会议"）。 本所律师通过视频通讯方式对本次会议进行见证，并根据《中华人民共和国 公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称 "《证券法》"）、《上市公司股东大会规则》（以下简称"《股东大会规则》"）、 《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律业务管理办 法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券 法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《北京康 辰药业股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议 的召集与召开程序、召集人资格、出席会议人员资格、会议表决程序及表决结果 等事宜，出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 1．本所律师仅就本次会议的召集与召开程序、召集人和出席现场会议人员 资格、会议表决程序及表决结果的合法性发表意见，不对本次会议所审议的议案 内容及该等议案所表述的事实或数据的真实性 ...

Financial Performance - "Su Ling" sales increased by 48.94% year-on-year in the first half of the year [3] - "Mi Gai Xi" sales revenue reached 134 million yuan in the first half, a slight decrease of 1.7% year-on-year [4] Market and Product Strategy - "Su Ling" benefited from national medical insurance renewal and restrictions lifting, with increased terminal coverage and academic activities [2] - "Su Ling" lifecycle management and pharmacoeconomic research continue to enhance product value [3] - "Mi Gai Xi" maintains a leading position in osteoporosis and acute bone loss treatment, with strong academic and clinical recognition [3] - Local centralized procurement in Zhejiang has minimal impact on "Mi Gai Xi" sales, accounting for only 8%-9% of total revenue [4] R&D and Clinical Progress - KC1036, a multi-target receptor tyrosine kinase inhibitor, has shown significant clinical efficacy in various solid tumors with over 100 cases enrolled [4] - Jin Cao Pian, a traditional Chinese medicine for chronic pelvic pain, is progressing well in Phase III clinical trials with over half of the 414 planned enrollments completed [4] - KC-B173, a recombinant human coagulation factor VIIa project, is advancing in preclinical studies with potential clinical benefits [5] Future Outlook and Strategic Initiatives - The company plans to further strengthen "Su Ling" product sustainability and expand market advantages [3] - The company is exploring the extension of "Su Ling" into the pet market, with a new drug application for canine hemocoagulase submitted in early July [4] - The company aims to accelerate the development of unmet clinical needs and high-market-potential indications for KC1036 [4] - A new equity incentive plan has been introduced to align with the company's ten-year strategic goals and motivate key personnel [5][6] Investor Relations - The investor relations meeting was held on August 1, 2023, via Tencent Meeting, with participation from major institutional investors [2][7][8]

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥450.84 million, representing a 21.33% increase compared to ¥371.59 million in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2023 was ¥92.89 million, up 13.23% from ¥82.04 million in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses surged by 146.93%, amounting to ¥84.83 million compared to ¥34.36 million in the same period last year[19]. - Basic earnings per share for the first half of 2023 were ¥0.59, a 13.46% increase from ¥0.52 in the same period last year[20]. - The total comprehensive income for the first half of 2023 was ¥198,701,482.10, significantly higher than ¥48,501,422.29 in the first half of 2022, marking an increase of 309.5%[138]. - The company reported a net profit margin of approximately -1.6% for the current period, indicating a challenging financial environment[148]. Cash Flow and Assets - The net cash flow from operating activities decreased by 33.67% to ¥43.95 million, down from ¥66.25 million in the previous year[19]. - The total assets of the company increased by 8.52% to ¥3.72 billion, compared to ¥3.42 billion at the end of the previous year[19]. - Cash and cash equivalents decreased to CNY 182,307,474.88 from CNY 345,245,428.47, a decline of 47.3%[126]. - The total cash and cash equivalents at the end of the period was CNY 96.32 million, down from CNY 483.59 million at the end of the first half of 2022, indicating a decrease of approximately 80%[144]. Research and Development - The company is actively conducting Phase II clinical trials for KC1036, a multi-target receptor tyrosine kinase inhibitor, showing an objective response rate (ORR) of 29.6% in late-stage esophageal squamous cell carcinoma[34][35]. - The company has a strong commitment to research and development, with multiple proprietary drugs in the pipeline addressing unmet clinical needs[34]. - Research and development expenses for the first half of 2023 were ¥40,286,678.85, compared to ¥35,648,617.69 in the previous year, showing an increase of 12.3%[134]. Product Development and Market Strategy - The main products include "Sulink," a first-class innovative hemostatic drug, and "Mige Xi," the only evidence-based drug for preventing acute bone loss[27][31]. - "Sulink" has been included in the National Basic Medical Insurance Drug List, allowing broader patient access and positively impacting long-term business development[28]. - The company is actively developing the first traditional Chinese medicine for chronic pelvic pain, Jin Cao Pian, which has shown significant improvement in abdominal pain symptoms during Phase II clinical trials[37]. - The company is expanding into the pet medicine market with the application for a new drug registration for a snake venom-derived hemostatic agent, which could be the first of its kind for pets[39]. Governance and Management - The company held its first extraordinary general meeting on January 13, 2023, where the election of the fourth board of directors was approved, including the nomination of JIN LI (Li Jing) as a non-independent director[82]. - The company experienced a change in management, with JIN LI (Li Jing) elected as a director and Liu Jianhua appointed as the chairman of the board on July 20, 2023[87]. - The company’s board of directors and supervisory board underwent a complete re-election process, ensuring compliance with legal regulations[86]. Environmental and Social Responsibility - The company has not faced any environmental issues or administrative penalties during the reporting period, emphasizing its commitment to green production and sustainable development[92]. - The company is recognized as a national green factory demonstration enterprise and adheres to the ISO 14001:2015 environmental management system, enhancing its environmental management practices[93]. - The company has implemented measures to reduce carbon emissions through refined management and technological innovations, achieving a reduction in energy consumption[96]. Shareholder and Equity Information - The total number of ordinary shareholders as of the end of the reporting period is 11,013[116]. - The top ten shareholders hold a total of 50,786,760 shares, representing 31.74% of the total shares[118]. - The company’s shareholders, including Beijing Gongtou, have completed their share reduction and no longer hold company stock as of April 1, 2023[105]. Financial Reporting and Compliance - The company’s financial reports and summaries for 2022 were disclosed on the Shanghai Stock Exchange, ensuring transparency for shareholders[82]. - The company’s internal control audit was conducted by Huaxing Accounting Firm, ensuring the integrity of financial reporting[85]. - The company adheres to accounting standards, ensuring that financial statements accurately reflect its financial position and performance[169].

证券代码：603590 证券简称：康辰药业 北京康辰药业股份有限公司 投资者关系活动记录表 编号：2023-01 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活 动类别 □新闻发布会 □路演活动 □现场参观 ■其他（线上会议） 参与单位名称 见附件 时间 2023 年 6 月 8 日 地点 腾讯会议 上市公司接待 人员姓名 刘笑寒（董事）、刘阳（IR） 会议主要就公司经营情况、财务情况、研发情况等进行了交流沟通，内 容如下： 1、公司近日股价调整，是什么情况呢？与最近市场传闻鲑降钙素进入浙 江集采相关吗？ 答：二级市场股价变动受诸多因素影响，公司目前经营正常，销售方面， 主营产品"苏灵"借助医保续约和解限契机，持续拓展增量医院、激活低活 投资者关系活 跃医院，销售正常开展；研发方面，在研项目 KC1036、金草片等项目正常推 动主要内容 进，不存在应披露未披露的重大事项。 介绍 公司也关注到近期传闻的浙江集采相关信息，公司从以下几个方面进行 回复： （1）公司产品"密盖息"，是诺华原研的创新药产品，是经 FDA 批准 的降钙素类药物，产品力好。目前原料药企业与公司签订独家供应协议，其 他 ...

证券代码：603590 证券简称：康辰药业 公告编号：临 2023-034 北京康辰药业股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络文字互动 投资者可于 2023 年 05 月 17 日(星期三)至 05 月 23 日(星期二)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@konruns.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 北京康辰药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 26 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 05 月 24 日下午 15:00-16:30 举行 2022 年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频结合网 ...

Financial Performance - In 2022, the company's operating revenue reached ¥866.73 million, an increase of 7.03% compared to ¥809.78 million in 2021[25]. - The net profit attributable to shareholders was ¥101.49 million, a decrease of 31.42% from ¥147.99 million in 2021[25]. - The net cash flow from operating activities increased by 68.79% to ¥119.69 million, compared to ¥70.91 million in 2021[25]. - Basic earnings per share decreased by 30.85% to ¥0.65, down from ¥0.94 in 2021[26]. - The weighted average return on equity fell to 3.49%, a decrease of 1.53 percentage points from 5.02% in 2021[26]. - The company's total assets at the end of 2022 were ¥3.42 billion, reflecting a 1.59% increase from ¥3.37 billion at the end of 2021[25]. - The company reported a decrease in net profit after deducting non-recurring gains and losses, which was ¥89.07 million, down 22.00% from ¥114.19 million in 2021[25]. - The company’s R&D expenses were 86.78 million RMB, down 15.15% from the previous year[90]. - The company’s sales expenses increased by 8.14% to 423.15 million RMB in 2022[90]. - The total sales expenses for the reporting period amounted to RMB 42,315.33 million, representing 48.82% of the operating income[140]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 2.00 per 10 shares to all shareholders based on the total number of shares eligible for distribution as of the dividend record date[6]. - The company approved a cash dividend of RMB 3.00 per 10 shares, totaling RMB 46,947,413.10, which represents 31.72% of the net profit attributable to ordinary shareholders in the consolidated financial statements[190]. - For the 2022 profit distribution plan, the company plans to distribute RMB 2.00 per 10 shares, amounting to RMB 31,298,275.40, which is 30.84% of the net profit attributable to ordinary shareholders[191]. Corporate Governance - The company has not faced any penalties from securities regulatory agencies in the past three years[175]. - The company has not reported any significant differences in governance compared to regulatory requirements[160]. - The company has engaged Beijing DeHeng Law Offices to ensure the legality of the shareholders' meeting procedures[163]. - The company continuously improves its corporate governance structure and enhances information disclosure in compliance with relevant laws and regulations[160]. - The company held a shareholders' meeting on March 16, 2022, where several resolutions were passed, including extending the validity period for non-public issuance of A shares[160]. - The company has not identified any major issues regarding the independence of its controlling shareholders or actual controllers[160]. - The company has expanded its board with independent directors, enhancing governance and oversight[169]. - The company has undergone changes in its board, with several directors resigning for personal reasons and new appointments made, including the election of JIN LI as a director[174]. Research and Development - The company is focused on innovative drug research and development, aiming to become a high-quality Chinese pharmaceutical brand with a commitment to quality-driven growth[66]. - The company has established a four-tier talent system to enhance its innovative drug development capabilities[41]. - The company has received three domestic and international invention patents in 2022, bringing its total to 56 authorized patents[45]. - The company is advancing its innovative drug pipeline, including KC1036 and Jin Cao Pian, with the latter currently in Phase III clinical trials[38]. - The company is actively developing the KC1036 project, a multi-target receptor tyrosine kinase inhibitor with potential anti-tumor effects[117]. - The company has multiple ongoing R&D projects, including AH1001 for canine surgical wound treatment and KC1036 for advanced thymic tumors[128]. - The company’s R&D investment as a percentage of operating income was 14.72%, while the capitalized R&D expenditure accounted for 31.98% of total R&D spending[135]. - The company has increased its investment in construction projects, with in-progress projects rising by 43.00% to 181,983,116.14 RMB[107]. Market Position and Strategy - The company anticipates that 2023 will bring significant opportunities for innovation in the pharmaceutical sector, driven by favorable policies for innovative drug products[35]. - The company aims to achieve a sales target of at least 100 million yuan for "Suling" in 2023 by managing core hospitals and activating low-activity hospitals[37]. - The company has been recognized as a "specialized, refined, distinctive, and innovative small giant" and is focusing on developing innovative drugs as its main growth strategy[36]. - The company is committed to high-quality development in the pharmaceutical industry, driven by the ongoing healthcare reform and the "14th Five-Year Plan" for the medical sector[62]. - The company aims to achieve continuous revenue growth by focusing on the sales of innovative drugs, particularly "Suling," which has been included in the National Basic Medical Insurance Directory[150]. - The company plans to leverage the opportunity of "Suling" medical insurance renewal and lifting restrictions to expand market share in 2023[87]. Risk Management - The company has outlined various risk factors and countermeasures that may affect its future development strategies and operational goals[10]. - The company acknowledges the impact of evolving industry policies and will proactively adapt to changes to mitigate risks and seize opportunities[157]. - The company is committed to addressing new drug development risks by intensifying resource allocation to key projects and enhancing collaboration with renowned research institutions[156]. Employee Management - The total number of employees in the parent company and major subsidiaries is 449, with 190 in sales, 100 in technology, and 82 in production[186]. - The company has established a three-tier training system to enhance employees' professional and managerial skills, covering various aspects including corporate culture and regulations[188]. - The company has implemented a salary policy that links compensation to company and individual performance, aiming to motivate employees[187]. - The company has established a performance evaluation mechanism for senior management, linking compensation to company performance and operational goals[198]. Legal and Compliance - The company has not reported any significant changes in competition or business operations affecting its independence[160]. - The company has not faced any non-operating fund occupation by controlling shareholders or related parties[8]. - The company has not violated decision-making procedures in providing guarantees to external parties[8]. - The company has made amendments to its articles of association and various management systems during the meetings[163].

Financial Performance - The company's operating revenue for Q1 2023 was ¥165,105,876.86, representing a year-on-year increase of 5.71%[5]. - The net profit attributable to shareholders decreased by 44.72% to ¥25,668,714.68, primarily due to non-recurring gains from the previous year[5][9]. - The net profit attributable to shareholders after deducting non-recurring gains increased by 229.85% to ¥22,709,397.16, driven by revenue growth from the "Su Ling" product[5][9]. - Basic and diluted earnings per share were both ¥0.16, down 46.67% year-on-year due to the decline in net profit[5][9]. - Operating profit for Q1 2023 was CNY 35,832,956.07, down 34.1% from CNY 54,408,108.46 in Q1 2022[21]. - Net profit for Q1 2023 was CNY 29,864,395.86, a decrease of 40.8% compared to CNY 50,440,303.82 in Q1 2022[21]. - Other comprehensive income after tax for Q1 2023 was CNY 81,339,307.08, compared to a loss of CNY 19,144,953.13 in Q1 2022[21]. - The total comprehensive income for Q1 2023 was CNY 111,203,702.94, significantly higher than CNY 31,295,350.69 in Q1 2022[21]. Cash Flow - The net cash flow from operating activities was ¥14,899,424.58, a decrease of 73.95% compared to the previous year, attributed to increased guarantee payments and reduced receivables[5][9]. - In Q1 2023, the cash inflow from operating activities totaled $213.58 million, a decrease of 9.2% compared to $235.25 million in Q1 2022[24]. - The net cash flow from operating activities was $14.90 million, down 73.9% from $57.19 million in the same period last year[24]. - Cash inflow from investment activities reached $571.83 million, significantly higher than $11.73 million in Q1 2022[25]. - The net cash flow from investment activities was -$117.83 million, slightly worse than -$114.98 million in Q1 2022[25]. - Cash inflow from financing activities amounted to $79.20 million, with a net cash flow of $76.60 million, compared to a net outflow of -$2.21 million in Q1 2022[25]. - The ending cash and cash equivalents balance was $306.65 million, down from $826.39 million at the end of Q1 2022[25]. - The company received $567.33 million from investment recoveries, a significant increase from $11.65 million in the previous year[25]. - The company paid $12.31 million for the purchase of fixed assets, down from $21.71 million in Q1 2022[25]. - The company reported a cash outflow of $2.59 million related to financing activities, compared to $2.21 million in Q1 2022[25]. - The impact of exchange rate changes on cash and cash equivalents was -$347,590.60, compared to -$117,902.72 in the previous year[25]. Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,597,910,506.27, an increase of 5.05% from the end of the previous year[6]. - The total current assets increased to RMB 1,239,735,492.32, compared to RMB 1,016,711,762.41 in the previous year[18]. - The company's cash and cash equivalents decreased to RMB 309,632,220.59 from RMB 345,245,428.47 year-on-year[17]. - Total liabilities as of Q1 2023 were CNY 296,581,437.26, compared to CNY 234,675,395.76 in Q1 2022, reflecting a 26.4% increase[20]. - The company reported a decrease in accounts payable from RMB 48,474,727.82 to RMB 23,210,002.07 year-on-year[18]. - The company's long-term equity investments slightly decreased to RMB 69,934,534.95 from RMB 70,277,736.99 year-on-year[18]. - The company's intangible assets increased to RMB 861,267,629.07 from RMB 812,748,642.27 year-on-year[18]. - Total equity increased to CNY 3,301,329,069.01 in Q1 2023 from CNY 3,190,125,366.07 in Q1 2022, representing a growth of 3.5%[20]. Research and Development - The company has initiated multiple clinical trials for KC1036, with over 100 advanced solid tumor subjects enrolled[14]. - KC1036 has shown significant clinical efficacy in various cancers, including esophageal, gastric, and lung adenocarcinoma, with a high patient compliance rate[15]. - The company is focused on accelerating the R&D process of KC1036 to bring it to market as soon as possible[15]. - R&D expenses increased to CNY 21,243,679.40 in Q1 2023, up 27% from CNY 16,729,400.94 in Q1 2022[20]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,352[10]. - Shareholders' equity attributable to the parent company increased by 3.66% to ¥3,032,915,967.80[6]. - The weighted average return on equity decreased by 0.74 percentage points to 0.86%[5].

Financial Performance - The company's revenue for Q3 2022 was CNY 216,398,655.98, representing a year-on-year increase of 53.43%[4] - The net profit attributable to shareholders for Q3 2022 was CNY 21,632,131.06, a decrease of 41.84% compared to the same period last year[4] - The basic and diluted earnings per share for Q3 2022 were both CNY 0.1382, down 41.42% year-on-year[5] - Total operating revenue for the first three quarters of 2022 was CNY 587,989,983.65, a decrease of 1.02% compared to CNY 596,601,169.14 in the same period of 2021[18] - Net profit for the third quarter of 2022 was CNY 114,524,803.30, down 19.5% from CNY 142,273,626.25 in the same quarter of 2021[19] - Earnings per share (EPS) for the third quarter was CNY 0.6625, compared to CNY 0.8703 in the same period last year, reflecting a decline of 23.8%[20] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,350,352,713.22, a decrease of 0.62% from the end of the previous year[5] - As of September 30, 2022, the company's total assets amounted to RMB 3,350,352,713.22, a slight decrease from RMB 3,371,320,206.37 at the end of 2021[14] - The company's cash and cash equivalents decreased to RMB 526,088,665.20 from RMB 599,081,775.25 year-over-year[14] - Accounts receivable stood at RMB 212,813,423.96, down from RMB 233,989,936.89 in the previous year[14] - Inventory decreased to RMB 36,771,327.00 from RMB 47,020,733.62 year-over-year[15] - The total current liabilities include accounts payable of RMB 34,082,140.55, down from RMB 46,738,357.06[15] - The company reported a total current asset of RMB 877,523,434.86, a decrease from RMB 947,828,654.54[15] - Total liabilities decreased to CNY 204,309,057.31 from CNY 240,742,477.76, indicating a reduction of approximately 15.1%[17] - Total equity increased slightly to CNY 3,146,043,655.91 from CNY 3,130,577,728.61, showing a growth of 0.5%[17] Cash Flow - The cash flow from operating activities for the year-to-date period was CNY 131,673,194.89[4] - Cash flow from operating activities for the first three quarters was CNY 637,284,307.52, an increase of 16.6% from CNY 546,405,533.47 in the previous year[21] - The net cash flow from operating activities was ¥131,673,194.89, a significant improvement compared to a negative cash flow of ¥13,107,096.52 in the previous year[22] - Total cash inflow from investment activities was ¥197,467,082.77, down from ¥545,031,259.27 year-over-year[22] - The net cash flow from investment activities was -¥148,145,514.08, an improvement from -¥337,588,982.48 in the same quarter last year[22] - Cash flow from financing activities resulted in a net outflow of -¥56,294,706.10, compared to a net inflow of ¥190,243,324.15 in the previous year[23] - The ending balance of cash and cash equivalents was ¥522,898,916.48, down from ¥949,024,851.44 year-over-year[23] Expenses and Income - The company experienced a significant increase in management expenses by approximately CNY 5 million and R&D expenses by approximately CNY 1 million, impacting net profit[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses for the year-to-date period was CNY 55,929,753.17, down 53.48% year-on-year[4] - The company reported a decrease in other income by CNY 670,540 compared to the previous year, primarily due to reduced government subsidies[9] - Total operating costs increased to CNY 506,473,397.64, up 9.8% from CNY 461,334,304.84 in the previous year[18] - Research and development expenses for the first three quarters were CNY 54,706,235.57, down 17.7% from CNY 66,439,112.06 in the previous year[18] - The company reported an investment income of CNY 28,272,233.60, significantly up from CNY 6,625,700.59 in the same period of 2021[18] - Other comprehensive income after tax for the third quarter was CNY -57,580,557.97, an improvement compared to CNY -184,425,114.31 in the previous year[20] Clinical Trials and Research - The company announced the approval of the ethical review for the Phase III clinical trial of Jincao Tablets on September 28, 2022[13] - The company is in discussions with Alvogen, Inc. regarding the clinical trial application for Teriparatide injection, which was withdrawn for further documentation[13] - The company plans to disclose further updates on the clinical trial progress of Jincao Tablets as it advances[13]

Financial Performance - The basic earnings per share for the first half of 2022 was CNY 0.52, a decrease of 17.46% compared to CNY 0.63 in the same period last year[21]. - The diluted earnings per share also stood at CNY 0.52, reflecting the same percentage decrease of 17.46% year-on-year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 60.60% compared to the previous year[21]. - The weighted average return on net assets was 2.86%, down by 0.50 percentage points from 3.36% in the same period last year[21]. - The company's operating revenue for the first half of the year was ¥371,591,327.67, a decrease of 18.43% compared to ¥455,557,666.78 in the same period last year[23]. - The net profit attributable to shareholders for the reporting period was ¥82,038,066.91, down 17.98% from ¥100,022,515.60 year-on-year[23]. - The net profit after deducting non-recurring gains and losses was ¥34,355,332.24, reflecting a significant decline of 60.60% compared to ¥87,201,380.13 in the previous year[23]. - The company reported a significant decrease in accounts receivable financing by 56.21%, down to ¥4,549,159.52, which is 0.14% of total assets[60]. - The company reported a net loss of approximately ¥46.95 million during the current period, reflecting a significant decrease compared to the previous period[151]. Cash Flow and Assets - The cash flow from operating activities increased compared to the same period last year, mainly due to a reduction in promotional service fees[21]. - The net cash flow from operating activities was ¥66,254,643.36, a notable improvement from a negative cash flow of ¥29,584,739.27 in the previous year[23]. - The company's cash and cash equivalents decreased by 6.30% to ¥561,359,820.33, representing 16.84% of total assets[60]. - The total cash and cash equivalents at the end of the period were ¥558,196,657.13, down from ¥980,979,883.10 at the end of the first half of 2021[143]. - The company reported a decrease in cash received from investment recoveries, totaling ¥189,373,420.33 compared to ¥479,585,264.66 in the first half of 2021[143]. - The company's total assets at the end of the reporting period were ¥3,333,060,355.19, down 1.13% from ¥3,371,320,206.37 at the end of the previous year[23]. - The company's total assets reached CNY 2,883,933,542.20, indicating a stable asset base despite the financial losses[157]. Research and Development - R&D expenses amounted to CNY 81.45 million, representing 21.92% of total revenue, with a significant increase of 50.61% year-on-year[52]. - The company is focusing on innovative drug development, with multiple new multi-target receptor tyrosine kinase inhibitors under research, including KC1036, CX1003, KC-B173, CX1026, and Jin Cao Pian[35][36][37][38][39][40][41][42]. - The company plans to enhance its R&D pipeline by collaborating with renowned domestic and international enterprises and research institutions[70]. - The company is focusing on key oncology drug development projects, aiming for expedited market entry through "pressure management" and increased R&D investment[70]. Market and Product Development - The company's main products include "Suling," a leading hemostatic agent, and "Mige Xi," a unique drug for preventing acute bone loss, both of which have established significant market positions[27][30]. - "Suling" has been widely used in over 2,000 hospitals across 31 provinces, helping millions of patients and saving nearly 100 tons of plasma annually[28]. - The company aims to enhance its market presence and profitability through continuous innovation and high-quality product development[27]. - The company plans to leverage its marketing capabilities to enhance sales of the acquired product "Mi Gai Xi," aiming for rapid business growth in the salmon calcitonin market[69]. Corporate Governance and Compliance - The company did not propose any profit distribution plan or capital reserve transfer to increase share capital for the reporting period[5]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[7]. - The company has not faced any environmental issues or administrative penalties during the reporting period, emphasizing its commitment to green production and sustainable development[82]. - The company has achieved ISO14001 and ISO50001 certifications, enhancing its environmental management and energy management systems[83]. - The company has committed to ensuring that the compensation measures for diluted immediate returns are effectively implemented by linking the remuneration system to the execution of these measures[101]. Strategic Partnerships and Acquisitions - The company has established strategic partnerships with German biotechnology firms and WuXi AppTec to enhance its product pipeline[49]. - The company has made performance commitments for the acquisition of "Mi Gai Xi" assets, with net profits of at least RMB 0.8 billion, 1 billion, and 1.2 billion for the years 2021, 2022, and 2023 respectively, totaling no less than RMB 3 billion over three years[102]. - The company is focusing on strategic mergers and acquisitions to enhance its competitive position in the market[150]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period was 17,241[117]. - The company completed the transfer of 1,994,900 shares to the first phase employee stock ownership plan at a price of 31.54 yuan per share, with a lock-up period of 36 months starting from the transfer date[80]. - The company has a profit forecast and compensation commitment for the period from 2021 to 2023[91]. - The company will announce any share reductions by Mu Ren Investment three trading days in advance, ensuring compliance with public commitments made during the IPO[99]. Financial Statements and Accounting Policies - The financial statements have been prepared based on the going concern assumption, indicating no significant issues affecting the company's ability to continue operations for at least 12 months[173]. - The company’s accounting policies comply with the requirements of the enterprise accounting standards, ensuring a true and complete reflection of its financial status[175]. - The preparation of consolidated financial statements is based on control, including subsidiaries determined by voting rights or contractual arrangements[182].